Coherus Oncology (CHRS) to Release Quarterly Earnings on Thursday

Coherus Oncology (NASDAQ:CHRS) is projected to announce its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $13.4130 million for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 5:00 PM ET.

Coherus Oncology Price Performance

Shares of CHRS stock opened at $1.60 on Tuesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.43 and a current ratio of 1.44. Coherus Oncology has a fifty-two week low of $0.66 and a fifty-two week high of $2.43. The firm has a market cap of $185.97 million, a P/E ratio of 1.03 and a beta of 0.96. The business’s 50 day moving average price is $1.53 and its 200-day moving average price is $1.12.

Hedge Funds Weigh In On Coherus Oncology

A number of hedge funds have recently added to or reduced their stakes in the company. Corient Private Wealth LLC boosted its stake in Coherus Oncology by 20.0% during the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 10,000 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Coherus Oncology in the second quarter worth $46,000. XTX Topco Ltd lifted its holdings in shares of Coherus Oncology by 65.3% during the second quarter. XTX Topco Ltd now owns 91,739 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 36,257 shares in the last quarter. Invesco Ltd. boosted its position in shares of Coherus Oncology by 11.5% during the second quarter. Invesco Ltd. now owns 208,271 shares of the biotechnology company’s stock valued at $152,000 after buying an additional 21,550 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its position in shares of Coherus Oncology by 52,980.1% during the first quarter. Acadian Asset Management LLC now owns 196,927 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 196,556 shares during the last quarter. 72.82% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CHRS has been the subject of a number of analyst reports. Maxim Group raised shares of Coherus Oncology from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a research note on Thursday, September 4th. Weiss Ratings reissued a “sell (d)” rating on shares of Coherus Oncology in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.51.

Coherus Oncology Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.